HC Wainwright & Co. Reiterates Buy on ArriVent BioPharma, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on ArriVent BioPharma (NASDAQ:AVBP) and maintained a $25 price target.
June 06, 2024 | 10:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on ArriVent BioPharma (NASDAQ:AVBP) and maintained a $25 price target.
The reiteration of a Buy rating and the maintenance of a $25 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100